Symbol
| DOCK2
| contributors: mct/pgu - updated : 06-09-2017
|
HGNC name
| dedicator of cyto-kinesis 2
|
HGNC id
| 2988
|
corresponding disease(s)
|
IMD40
|
Variant & Polymorphism
|
| |
Candidate gene
Marker
Therapy target
|
System | Type | Disorder | Pubmed |
neurology | neurodegenerative | alzheimer | |
DOCK2 is a COX2 expression-independent therapeutic target for neurodegenerative diseases such as AD | immunology | | | |
therapeutic target for immunologic disorders caused by lymphocyte infiltration | cancer | hemopathy | | |
is a potential therapeutic target for novel AML treatments, as this protein regulates the survival of leukemia cells with elevated FLT3 activity and sensitizes FLT3/ITD leukemic cells to conventional antileukemic agents |
| | | |
| T-lymphoid progenitor cells in fetal mice express two closely related CDM family molecules, Dock2 and Dock1, and and the impaired fetal thymus colonization in mice deficient for Dock2 and Dock1 was not as severe as that in mice doubly deficient for Ccr7 and Ccr9 |